New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
10:25 EDTSGYP, SGYPSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Synergy Pharmaceuticals' (SGYP) Plecanatide for Irritable Bowel Disease with constipation on an Analyst/Industry conference call to be held on April 17 at 11 am.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
06:06 EDTSGYPSynergy Pharm' presents positive data from phase 2b study of plecanatide
Synergy Pharmaceuticals announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients with irritable bowel syndrome with constipation. Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period. Notably, patients taking 3.0 and 9.0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use